The major representatives of the molecular markers used to predict prognosis and to plan treatment strategies for DCIS and IDC are the estrogen and progesterone receptors (ER and PR) and the erbB2 protein, which are in current clinical use in most cancer treatment centers. The ERBB2 gene is overexpressed in approximately 30% of invasive breast tumors and more than 60% of ductal in situ tumors, and transcribes a transmembrane glycoprotein -erbB2 -involved in cell growth control. The protein is part of the epidermal growth factor receptor family and has tyrosine-kinase function (4). Estrogen is one of the most important factors for growth stimulation and cell development in breast cancer. Its receptor is part of the nuclear receptor family. The alpha receptor is overexpressed in more than half of all breast cancers, and almost 70% of these respond to tamoxifen treatment (5, 6).
INTRODUCTION
There is a growing body of evidence supporting the concept that the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) is regulated by a small number of genes (1) . More than 50% of DCIS evolve to IDC, despite the high variability in time for this progression. Between 11% and 20% of DCIS are associated with invasive carcinoma when entirely excised, and recurrence in 1-32% of these tumors may occur in an invasive form. The main changes in gene expression patterns occur during the transition from normal tissue to DCIS, instead of at the stage when DCIS is progressing to IDC (2) . Pathological characteristics alone have been proven to be insufficient to predict the clinical behavior of DCIS, leaving room for biomolecular markers of tumor malignization potential (3) . However, the molecular mechanisms controlling the transition from DCIS to IDC are still poorly understood. appointing results. For instance, with the exception of the study by Provenzano et al (7) , most reports concur in the finding that hormone receptor status is not an important prognostic factor in DCIS. The same is true with regard to the expression of the erbB2 protein, as most studies concluded that it is not a prognostic factor in DCIS independent of standard pathological parameters (8, 9) .
Because of several methodological limitations, however, these studies are far from being conclusive as to how hormone receptor and erbB2 status behave within breast tumors that harbor both DCIS and IDC components. Firstly, although some studies suggest that IDC that develops around erbB2-positive DCIS may not feature a erbB2-positive status -a finding that has led many investigators to suspect that ERBB2 gene amplification may not be required for the progression of DCIS to IDC (10) -none have examined the expression of these markers at the precise region of the contiguous areas from DCIS to IDC. Moreover, most of the previous studies analyzed separate sets of women with DCIS and IDC, that is, they did not compare the expression of these molecules in DCIS and IDC in the same specimen.
The only study design capable of overcoming the aforementioned difficulties would be by identifying DCIS and IDC in the same region of surgical breast specimens and determining the expression of the molecules of interest in these contiguous areas. Such a study design requires precision techniques of histological sampling, because distant areas of DCIS and IDC, even if collected from the same woman, may have emerged from different mutant cell lines. We therefore decided to conduct the present study in which we sampled contiguous areas of DCIS and IDC. We determined the expression of ER/PR and erbB2 at the precise areas where DCIS turned into IDC, in an attempt to rule out the confounding effects of examining lesions originating from different cell clones or even from women with discrepant epidemiological and genetic backgrounds.
Materials and Methods

Patients
Samples of breast malignancies harboring regions of DCIS and IDC were selected from women who had been treated with surgery at the breast cancer clinics of the State University of Campinas, São Paulo, Brazil, from 2005 to late 2008. Clinical and epidemiological characteristics were retrieved from the patients' medical records. The study protocol was fully approved by the institution's ethics review board (CEP #705/2007 and #314/2008). Because of the retrospective nature of the study, the obligation to obtain signed informed consent from the women was waived.
Specimens
The tissue microarray technique (TMA) was applied to newly made paraffin blocks containing cylindrical tissue areas from the original blocks. For the present study, hematoxylin and eosin (H&E) slides were produced from preselected original paraffin blocks with contiguous areas of DCIS and IDC. An experienced pathologist used these slides to identify the best and most representative areas of DCIS and IDC for TMA analysis. One of the major concerns was that the selected areas must be contiguous. Based on the pathologist's directions, tissue cylinders of 1 mm in diameter were obtained from the original tumor blocks and arrayed into a single recipient paraffin block at high density. Sections were sliced from this new block and immunohistochemistry (IHC) was performed on the new slides.
Assay methods
Immunohistochemistry
Sections were deparaffinized with xylol and dehydrated through graded alcohol series. They were then washed with hydrogen peroxide followed by distilled water. Steam was used for antigen retrieval and the slide was immersed in citrate buffer pH 6.0 for 30 minutes. It was dried at room temperature and washed in distilled water. The slide was then incubated in a moist chamber with the specific primary antibody at 4ºC overnight (erbB2: clone CB11/dilution 1:200, Novocastra; ER: clone 6F11/ dilution 1:80, Novocastra; PR: clone PGR312/dilution 1:100, Novocastra). It was washed in PBS pH 7.4-7.6. As a detection system, the slide was incubated in Novolink Max Polymer (Novocastra) at 37ºC for 1 hour and washed in PBS. DAB chromogenic substrate (3'-diaminobenzidine, SIGMA, #D5637) was applied at a proportion of 0.06 g to 100 mL of PBS, 500 μL hydrogen 3% peroxide and 1 mL dimethylsulfoxide (DMSO) at 37ºC for 5 minutes. Finally, the slide was washed in tap water and counterstained with Harris' hematoxylin. After being dehydrated, it was mounted in resin (Entellan®). Internal and external positive and negative controls were used in order to validate the reactions.
Fluorescence in situ hybridization (FISH)
The slides were incubated in the oven at 56°C and dehydrated through graded alcohol series. In order to remove residual paraffin, xylol baths were performed. The slides were washed in alcohol and incubated in 2×SSC at 75°C for 20 minutes. Proteinase K (0.25 mg/ mL) was used for digestion at 45°C for 20 minutes. The slides were washed in tap water and dehydrated in alcohol series. The probe HER-2 DNA Probe Kit (Vysis, cod 36.161060) and the slides were denatured at 75°C and at 80°C, respectively, for 5 minutes. Dehydration was performed. The probe was applied to the slides, which were sealed with rubber cement and placed in the oven at 37°C overnight. Post-hybridization washes were performed in 1.5 M urea/1×SSC for 30 minutes and 2×SSC for 5 minutes. After dehydration, the slides were counterstained with DAPI and visualized with a fluorescence microscope.
Image analysis
The IHC staining and FISH signals were assessed independently by a single observer who was uninformed of the clinical and pathological features of the disease. Two TMA sets of each tumor component were used for each marker, i.e., each tumor area was assessed twice. For IHC, in post-hoc analysis, if scores differed in the 2 analyses, the stronger staining was considered. Membranous IHC staining was considered for erbB2 and nuclear staining for ER/PR. erbB2 IHC staining was graded using a 4-stain pattern score: 1) 0 (negative): no staining or membrane staining in <10% of tumor cells; 2) 1+: faint membrane staining in >10% of tumor cells; 3) 2+: weak/moderate complete membrane staining in >10% of tumor cells, and 4) 3+: strong complete membrane staining in >10% of tumor cells (11) . The ER/PR continu-ous percentage of IHC-stained nuclei was further categorized in 3 ways: 1) negative: less than 10% of stained nuclei; 2) 10% to 50% of stained nuclei, and 3) >50% of stained nuclei.
In FISH analysis, the signals observed were classified as <2, 2 or >2, and a gain or loss status was inferred from this result.
For statistical purposes, a dichotomous final erbB2 status was defined using a combination of the IHC and FISH results. Positive erbB2: 1) IHC 2+ / FISH positive; or 2) IHC 3+ / FISH negative; or 3) IHC 3+ / FISH positive. Negative erbB2: 1) IHC negative / FISH negative; or 2) IHC 2+ / FISH negative.
Statistical analysis
All statistical calculations were performed with the R environment for statisticalcomputing (12) . Confidence levels were set at 5% (p=0.05). The paired t-test was used to compare the expression of erbB2 and ER/PR in the in situ and invasive components of the breast lesions. Finally, intraclass correlation coefficients (ICC) were calculated to assess agreement in the cross-tabulation of erbB2 and ER/PR scores obtained in the in situ and invasive regions of the breast tumors. 
RESULTS
Most women were 49 years of age or older at the moment of the diagnosis. The majority of the patients had disease that had already extended to the axilla (59%), and tumors larger than 2.0 cm were harbored by more than 60% of the women, resulting in a high (47%) proportion of advanced disease (stages III-IV). Considering the in situ component of the tumors, 38% of the cases were classified as comedo-type, or high grade. The vast majority of the invase components was also high grade (histological grade = 3) (Tab. I).
The positivity rate for erbB2 was similar in the invasive and in situ components (p=0.35). Approximately 28% of the invasive components were scored as positive for the transmembrane receptor, compared to 21% of the in situ components. While approximately 53% of the invasive regions were negative for ER, only 42% of the in situ samples did not express the marker. The majority of the samples in both groups expressed PR in >50% of the cells. The PR status was not statistically different between the in situ and invasive regions of the tumors (p=0.06). By contrast, there was a slight imbalance in ER status (p=0.04). Samples with strong expression of ER were 26% in in situ areas compared to 22% in the invasive component (Tab. II).
Corroborating the results presented in the previous paragraph, there was a good agreement in sample-bysample comparisons of the expression gradients of erbB2 (ICC=0.78), PR (ICC=0.61) and ER (ICC=0.70) in the in situ and invasive components of the breast tumors (Tab. III).
DISCUSSION
In the present study we detected similar expressions of the 3 most used biological markers for breast cancer in the neighboring areas of their in situ and invasive components. To the best of our knowledge, the present study is the first attempt at examining the expression of these markers where DCIS and IDC are topographically close to each other; hypothetically in the region where DCIS is acquiring its potential to invade. It is reasonable to infer that the transition to invasiveness is occurring at these locations, and that the molecular processes that lead to invasion are active there. Combined to the findings of a few previous and methodologically different studies, several implications and theoretical inferences may be derived.
The information about hormone receptor status and expression of erbB2 protein as related to tumor invasiveness is also limited, justifying the present study (13) . The transmembrane expressions of hormone (estrogen and progesterone) receptors and erbB2 protein are examples of consolidated predictive factors in breast tumors. The role of the lesions' morphological characteristics has been explored to its full potential, and comprehensive classifi- (22) IHC, immunohistochemistry; FISH, fluorescence in situ hybridization cations of ductal in situ lesions based on morphology are widely used and provide some useful information. ERBB2 gene amplification in breast cancer has been associated with increased cell proliferation, cell motility, tumor invasiveness, progressive regional and distant metastases, accelerated angiogenesis, and reduced apoptosis (13) . However, there is little information about its action in tumor progression from in situ to invasiveness. Castro and colleagues (14) recently reported results that, in spite of several methodological differences, are in full agreement with our findings. After analyzing the gene expression signatures of epithelial cells isolated by laser capture microdissection, they found that cells derived from DCIS specimens associated with invasive cancer displayed very similar gene signatures compared to cells from the invasive component of the tumor. By contrast, cells isolated from pure DCIS had substantially different gene signatures compared to those isolated from tumors with an invasive component. The authors proposed 2 possible explanations for their findings: 1) a small number of genes regulate the transition from DCIS to IDC, and 2) the major molecular alterations associated with invasion precede the morphological changes observed through light microscopy. These are sensible explanations to our findings as well, although we may add that, if they are true, we would expect that the molecular alterations which occur before the morphological invasion persist in the invasive form of the tumor.
There are also current lines of evidence suggesting that morphological features of invasion at light microscopy are manifested only after major molecular alterations. These molecular alterations should compound with microenvironmental factors (possibly related to the biological be-havior of myoepithelial cells and stromal cells) in order for DCIS to evolve to IDC (14) . These microenvironmental factors may explain why some DCIS progress to IDC while other DCIS lesions with similar molecular profiles do not, which supports the hypothesis of a multifactorial background for the progression of the disease.
Importantly, neither Castro's nor our study answered the question as to whether erbB2 is, in fact, involved in the acquisition of the capacity for invasiveness by epithelial lesions. Both studies just provide the information that DCIS and invasive components of a given breast lesion have similar molecular profiles. Another large study produced results that are in line with ours. Park and colleagues (10) after analyzing 50 cases of pure DCIS and 270 cases of IDC with intraductal and invasive components detected that the ERBB2 gene was amplified in 50% of DCIS and 30% of IDC with intraductal components, which is in agreement with previous studies (9, 15, 16) . However, their most relevant finding was that the erbB2 expression in the intraductal component of IDC was similar to that of the associated invasive component. They acknowledge that these results might be hampered by the small sample of pure DCIS compared to IDC.
The association of an erbB2-positive status with specific pathological conditions of the breast has been studied extensively during the last decade. erbB2 overexpression has been consistently associated with higher grades and extensive forms of DCIS and DCIS displaying comedo-type necrosis (17) (18) (19) (20) . The prevalence of erbB2 positivity was found to range from 24% to 38%, which is slightly higher than in invasive cancer. In a previous study, using only immunohistochemistry and reporting on roughly the same sample of breast tumors, we detected the same trend, as 2+ and 3+ erbB2 expression was 34% and 47% for IDC and DCIS, respectively (21) . It is important to mention that the higher proportion of erbB2 positivity in our sample compared to that reported in other studies may be due to the clinical and epidemiological features of our sample, with a large number of high-grade and advanced cases. The large number of advanced cases is probably a consequence of the inadequate efficacy of the Brazilian public health system screening strategy, and we are unable to avoid this sample bias. In our study, the TMA technique allowed precision sampling of the contiguous areas from DCIS to IDC. However, some methodological questioning may be elicited by this approach, and we must anticipate that protein expression identification and gene evaluation by immunohistochemistry and FISH can be safely applied in combination with the TMA technique, which was first described by Kononen et al in 1998 (22) . Although some uncertainties have been raised about the use of TMA rather than conventional histological sections, studies have suggested that there is more than 95% concordance between the 2 techniques in detecting the expression of erbB2 protein and ER/PR analysis. Another important methodological aspect, which can be interpreted as a flawed case selection, is the relatively high proportion of high-grade tumors in our sample. This characteristic may be responsible for the elevated prevalence of erbB2-positive tumors. As per study design, we tried to avoid this possible pitfall by using paired comparisons of the expression of the tumor markers, i.e., comparing the expression of erbB2 and ER/ PR in the same specimen in the in situ and invasive components in all analyses, thereby offsetting the effect of the high proportion of high-grade cases on the prevalence of the tumor markers in each component.
Our study, while focusing its analysis on the transition from one component to the other, examines a tumor region where important steps of the carcinogenic process occur. The in situ and invasive components of breast tumors have been shown before to display similar molecular profiles, and our findings are in line with the theory that neither erbB2 status nor ER/PR expression play a relevant role in the progression from DCIS to IDC.
